With the introduction of PSMA PET ligands a decade ago, the landscape of prostate cancer (PC) management has shifted profoundly, and accordingly, the international and national guidelines have appreciated the added value of PSMA imaging through its implementation in routine clinical practice [1–5]. The gene discussed is FOLH1; the disease is pachyonychia congenita.